Alongside a previous report [49], these pre-clinical findings suggest that combined olaparib/AZD6738 treatments may provide more durable responses than single-agents in ATM-deficient tumours across multiple tissues types with varying degrees of ATM-deficiency. Here, ATM is linked to neoplasm.